Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date: June 14, 2024
Context: The filing discloses updated clinical trial data presented at the European Hematology Association 2024 Congress regarding three investigational assets: bitopertin for erythropoietic protoporphyria (EPP), DISC-0974 for myelofibrosis (MF) anemia, and DISC-3405.
Key Financial Metrics
This Form 8-K is a current report focused on clinical developments and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data Updates
Bitopertin (EPP)
- AURORA Trial (Phase 2): Enrolled 75 adults randomized to 20 mg, 60 mg, or placebo.
- 60 mg group showed a 40% reduction in protoporphyrin IX (PPIX) vs. placebo.
- Time-dependent improvement in light tolerance was nominally significant for both 20 mg (p=0.026) and 60 mg (p=0.013) groups.
- Post-hoc analysis showed ~2x improvement in light tolerance vs. baseline for both dose groups.
- 75.3% reduction in phototoxic reaction rate for the 60 mg group (p=0.011).
- Statistically significant improvement in Patient Global Impression of Change (PGIC) for the 60 mg dose (p=0.022).
- No serious adverse events (SAEs) reported to date.
- BEACON Trial: Full adult data set presented; results consistent with prior data and similar to AURORA.
DISC-0974 (Myelofibrosis Anemia)
- Phase 1b/2a Trial: Updated data from 34 patients (cutoff April 29, 2024).
- Substantial, sustained reductions in hepcidin and increases in iron observed.
- 68.9% of non-transfusion dependent (nTD) participants achieved hemoglobin response ≥1.5 g/dL.
- 60% of nTD participants completing ≥16 weeks sustained hemoglobin response ≥1.5 g/dL for ≥12 weeks.
- One of two evaluable transfusion-dependent (TD) participants became transfusion independent.
- 6 of 10 participants on concomitant JAK inhibitor therapy achieved hemoglobin response ≥1.5 g/dL.
- All evaluable participants with baseline transfusion requirements showed ≥50% reduction in transfusions over an 8-week window.
- Generally well-tolerated at all dose levels.
DISC-3405 (Healthy Volunteers)
- Phase 1 SAD Trial: Initial data from single ascending dose cohorts.
- Dose-dependent increase in hepcidin and reduction in serum iron across all levels.
- Mean serum iron reduction >50% achieved in 150 mg and 300 mg dose groups.
- 300 mg group sustained >50% iron reduction for at least 4 weeks.
- PK/PD profile supports monthly subcutaneous dosing.
- No SAEs, Grade 2+ adverse events, or withdrawals reported.
Guidance, Outlook, and Risks
Outlook: The Company hosted a live webcast on June 14, 2024, and updated its corporate presentation. All three assets (bitopertin, DISC-0974, DISC-3405) remain investigational and are not approved for use in any jurisdiction.
Risks: The filing explicitly states that the Company undertakes no obligation to update, supplement, or amend the attached materials. Information on the Company's website is not incorporated by reference.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) for detailed statistical tables not fully summarized in the 8-K text.
- Confirm the specific safety profile and adverse event details beyond the "no SAEs" summary for each trial.
- Review the Company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor upcoming regulatory interactions or trial design changes for bitopertin following the AURORA and BEACON data readouts.
- Check for any subsequent filings regarding the Phase 1b/2a expansion of DISC-0974 or Phase 1b of DISC-3405.